|1.||Sun, Wei: 1 article (01/2015)|
|2.||Liu, Zhong-Yan: 1 article (01/2015)|
|3.||Li, Xin-Ping: 1 article (01/2015)|
|4.||Sun, Jian-Jun: 1 article (01/2015)|
|5.||Fan, Yue-Zu: 1 article (01/2015)|
|6.||Zhu, Wei: 1 article (01/2015)|
|7.||Jing, Wei: 1 article (01/2015)|
|8.||Zhang, Jing-Tao: 1 article (01/2015)|
|9.||Ylä-Herttuala, Seppo: 1 article (11/2010)|
|10.||Närvänen, Ale: 1 article (11/2010)|
11/01/2010 - "In addition, after 48 h two of five tumor-bearing mice showed a clear accumulation of the In-labeled mF4-31C1 at the left axillary area. "
11/01/2010 - "Accumulation of mF4-31C1 antibody in the lymph nodes suggests the remote activation of VEGFR-3 by the primary tumor."
11/01/2010 - "Both intravenously administered antibodies could also be detected from the tumor sections by immunohistological staining but only mF4-31C1 forms in the lymph nodes. "
11/01/2010 - "The tumor uptake was 8.78 ± 0.74 %ID/g for cetuximab and 5.77 ± 0.62 %ID/g for mF4-31C1 after 48 h postinjection. "
01/01/2015 - "Furthermore, the expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 at protein/mRNA levels in the process of lymphatic tube formation in vitro and tumor lymphangiogenesis in vivo was downregulated; NCTD in combination with mF4-31C1 or Sorafenib enhanced these effects. "
|1.||Vascular Endothelial Growth Factor Receptor-3 (Flt 4)
|2.||Vascular Endothelial Growth Factor D
|3.||Vascular Endothelial Growth Factor C
|4.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|5.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|6.||Messenger RNA (mRNA)
|9.||sorafenib (BAY 43-9006)
|1.||Heterologous Transplantation (Xenotransplantation)